Q2 2015 13F Holders as of 6/30/2015
-
Type / Class
-
Debt / NOTE 4.500% 7/1
-
Number of holders
-
16
-
Total principal
-
113M
-
Principal change
-
-3.53M
-
Total reported value, excl. options
-
$238M
-
Value change
-
-$7.11M
-
Number of buys
-
5
-
Number of sells
-
-8
-
Price
-
$2.10
Significant Holders of MERRIMACK PHARMACEUTICALS IN - NOTE 4.500% 7/1 as of Q2 2015
14 filings reported holding 590328AA8 - MERRIMACK PHARMACEUTICALS IN - NOTE 4.500% 7/1 as of Q2 2015.
MERRIMACK PHARMACEUTICALS IN - NOTE 4.500% 7/1 has 16 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $113M of principal
.
Largest 10 bondholders include Citadel Advisors LLC ($26.2M of principal), SILVERBACK ASSET MANAGEMENT LLC ($16.7M of principal), Polygon Management Ltd. ($16.5M of principal), WOLVERINE ASSET MANAGEMENT LLC ($12.6M of principal), ARISTEIA CAPITAL LLC ($10.9M of principal), LAZARD ASSET MANAGEMENT LLC ($9.01M of principal), Ameriprise Financial Inc ($3.56M of principal), TANG CAPITAL MANAGEMENT LLC ($3.5M of principal), JPMORGAN CHASE & CO ($3.43M of principal), and Polar Capital LLP ($3.28M of principal).
This table shows the top 16 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.